Evelo Biosciences

Founded in 2015, Evelo Biosciences has established the leading therapeutics discovery and development platform based on the human immuno-microbiome, the inter-connected metasystem comprising the immune system and the microbiome.  Evelo’s development of microbes as pharmacological agents – onco-microbials and immuno-microbials – offers new approaches to important unmet needs in cancer, and immuno-inflammatory diseases such as psoriasis, ulcerative colitis, rheumatoid arthritis, food allergies, multiple sclerosis and other neuroinflammatory diseases. The company is translating its insights into the immuno-microbiome into a range of product candidates, which are being advanced toward first human testing in 2018.


Company Profile

Evelo Biosciences Logo

Flagship Partners:

  • Noubar Afeyan, Founder & CEO
  • David Berry, General Partner